Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …

Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis
of this variability remains poorly understood. We performed prospective targeted sequencing …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Abstract The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …

The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer.
Although RAS mutations are the most frequent MAPK alterations, less frequent alterations in …

Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …